{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:15:49Z","timestamp":1793330149861,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The identification of brain-targeted autoantibodies in children with autism spectrum disorder (ASD) raises the possibility of autoimmune encephalopathy (AIE). Intravenous immunoglobulin (IVIG) is effective for AIE and for some children with ASD. Here, we present the largest case series of children with ASD treated with IVIG. Through an ASD clinic, we screened 82 children for AIE, 80 of them with ASD. IVIG was recommended for 49 (60%) with 31 (38%) receiving the treatment under our care team. The majority of parents (90%) reported some improvement with 71% reporting improvements in two or more symptoms. In a subset of patients, Aberrant Behavior Checklist (ABC) and\/or Social Responsiveness Scale (SRS) were completed before and during IVIG treatment. Statistically significant improvement occurred in the SRS and ABC. The antidopamine D2L receptor antibody, the anti-tubulin antibody and the ratio of the antidopamine D2L to D1 receptor antibodies were related to changes in the ABC. The Cunningham Panel predicted SRS, ABC, parent-based treatment responses with good accuracy. Adverse effects were common (62%) but mostly limited to the infusion period. Only two (6%) patients discontinued IVIG because of adverse effects. Overall, our open-label case series provides support for the possibility that some children with ASD may benefit from IVIG. Given that adverse effects are not uncommon, IVIG treatment needs to be considered cautiously. We identified immune biomarkers in select IVIG responders but larger cohorts are needed to study immune biomarkers in more detail. Our small open-label exploratory trial provides evidence supporting a neuroimmune subgroup in patients with ASD.<\/jats:p>","DOI":"10.1038\/s41398-018-0214-7","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T15:40:31Z","timestamp":1533915631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism"],"prefix":"10.1038","volume":"8","author":[{"given":"Kathleen","family":"Connery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.","family":"Delhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-4367","authenticated-orcid":false,"given":"Shannon","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Slattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Kahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1078-4203","authenticated-orcid":false,"given":"Juergen","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine W.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-2937","authenticated-orcid":false,"given":"Richard E.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"214_CR1","first-page":"1","volume":"13","author":"B Zablotsky","year":"2015","unstructured":"Zablotsky, B., Black, L. I., Maenner, M. J., Schieve, L. A., & Blumberg, S. J. Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 National Health Interview Survey. National Health Stat. Reports 13, 1\u201320 (2015).","journal-title":"National Health Stat. Reports"},{"key":"214_CR2","first-page":"CD009260","volume":"10","author":"B Reichow","year":"2012","unstructured":"Reichow, B., Barton, E. E., Boyd, B. A. & Hume, K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst. Rev. 10, CD009260 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"214_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/mp.2011.165","volume":"17","author":"DA Rossignol","year":"2012","unstructured":"Rossignol, D. A. & Frye, R. E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 17, 389\u2013401 (2012).","journal-title":"Mol. Psychiatry"},{"key":"214_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.bbr.2014.09.032","volume":"278","author":"KA Foley","year":"2015","unstructured":"Foley, K. A., MacFabe, D. F., Kavaliers, M. & Ossenkopp, K. P. Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: relevance to autism spectrum disorders. Behav. Brain Res. 278, 244\u2013256 (2015).","journal-title":"Behav. Brain Res."},{"key":"214_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087072","volume":"9","author":"KA Foley","year":"2014","unstructured":"Foley, K. A., Ossenkopp, K. P., Kavaliers, M. & Macfabe, D. F. Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner. PLoS. ONE 9, e87072 (2014).","journal-title":"PLoS. ONE"},{"key":"214_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature10907","volume":"484","author":"NC Derecki","year":"2012","unstructured":"Derecki, N. C. et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105\u2013109 (2012).","journal-title":"Nature"},{"key":"214_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/mp.2014.59","volume":"20","author":"A Masi","year":"2015","unstructured":"Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R., Hickie, I. B. & Guastella, A. J. Cytokine abberations in autism spectrum disorder: a systematic review and meta-analysis. Mol. Psychiatry 20, 440\u2013446 (2015).","journal-title":"Mol. Psychiatry"},{"key":"214_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fphys.2014.00150","volume":"5","author":"DA Rossignol","year":"2014","unstructured":"Rossignol, D. A. & Frye, R. E. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Front. Physiol. 5, 150 (2014).","journal-title":"Front. Physiol."},{"key":"214_CR9","doi-asserted-by":"publisher","unstructured":"Frye R. E., Slattery J. C., Quadros E. V. Folate metabolism abnormalities in autism: potential biomarkers. Biomark Med. (2017). https:\/\/doi.org\/10.2217\/bmm-2017-0109.","DOI":"10.2217\/bmm-2017-0109"},{"key":"214_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jcma.2015.01.008","volume":"78","author":"S Bashir","year":"2015","unstructured":"Bashir, S. & Al-Ayadhi, L. Endothelial antibody levels in the sera of children with autism spectrum disorders. J. Chin. Med. Assoc. 78, 414\u2013417 (2015).","journal-title":"J. Chin. Med. Assoc."},{"key":"214_CR11","doi-asserted-by":"publisher","first-page":"935608","DOI":"10.1155\/2013\/935608","volume":"2013","author":"M Careaga","year":"2013","unstructured":"Careaga, M., Hansen, R. L., Hertz-Piccotto, I., Van de Water, J. & Ashwood, P. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediat. Inflamm. 2013, 935608 (2013).","journal-title":"Mediat. Inflamm."},{"key":"214_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbi.2010.11.017","volume":"25","author":"P Goines","year":"2011","unstructured":"Goines, P. et al. Autoantibodies to cerebellum in children with autism associate with behavior. Brain Behav. Immun. 25, 514\u2013523 (2011).","journal-title":"Brain Behav. Immun."},{"key":"214_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-39","volume":"8","author":"GA Mostafa","year":"2011","unstructured":"Mostafa, G. A. & Al-Ayadhi, L. Y. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. J. Neuroinflamm. 8, 39 (2011).","journal-title":"J. Neuroinflamm."},{"key":"214_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ejpn.2011.12.010","volume":"16","author":"GA Mostafa","year":"2012","unstructured":"Mostafa, G. A. & Al-Ayadhi, L. Y. The relationship between the increased frequency of serum antineuronal antibodies and the severity of autism in children. Eur. J. Paediatr. Neurol. 16, 464\u2013468 (2012).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"214_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pediatrneurol.2008.10.017","volume":"40","author":"GA Mostafa","year":"2009","unstructured":"Mostafa, G. A. & Kitchener, N. Serum anti-nuclear antibodies as a marker of autoimmunity in Egyptian autistic children. Pediatr. Neurol. 40, 107\u2013112 (2009).","journal-title":"Pediatr. Neurol."},{"key":"214_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.50","volume":"3","author":"D Braunschweig","year":"2013","unstructured":"Braunschweig, D. et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl. Psychiatry 3, e277 (2013).","journal-title":"Transl. Psychiatry"},{"key":"214_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbi.2013.12.020","volume":"38","author":"IS Piras","year":"2014","unstructured":"Piras, I. S., Haapanen, L., Napolioni, V., Sacco, R., Van de Water, J. & Persico, A. M. Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder. Brain Behav. Immun. 38, 91\u201399 (2014).","journal-title":"Brain Behav. Immun."},{"key":"214_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2013.01.084","volume":"30","author":"CW Nordahl","year":"2013","unstructured":"Nordahl, C. W. et al. Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. Brain Behav. Immun. 30, 61\u201365 (2013).","journal-title":"Brain Behav. Immun."},{"key":"214_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1126\/science.8430330","volume":"259","author":"P Greengard","year":"1993","unstructured":"Greengard, P., Valtorta, F., Czernik, A. J. & Benfenati, F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 259, 780\u2013785 (1993).","journal-title":"Science"},{"key":"214_CR20","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1016\/S0021-9258(19)76576-4","volume":"263","author":"LC Griffith","year":"1988","unstructured":"Griffith, L. C. & Schulman, H. The multifunctional Ca2\u2009+\u2009\/calmodulin-dependent protein kinase mediates Ca2\u2009+\u2009-dependent phosphorylation of tyrosine hydroxylase. J. Biol. Chem. 263, 9542\u20139549 (1988).","journal-title":"J. Biol. Chem."},{"key":"214_CR21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","volume":"30","author":"K Chakrabarty","year":"2005","unstructured":"Chakrabarty, K., Bhattacharyya, S., Christopher, R. & Khanna, S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30, 1735\u20131740 (2005).","journal-title":"Neuropsychopharmacology"},{"key":"214_CR22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm892","volume":"9","author":"CA Kirvan","year":"2003","unstructured":"Kirvan, C. A., Swedo, S. E., Heuser, J. S. & Cunningham, M. W. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat. Med. 9, 914\u2013920 (2003).","journal-title":"Nat. Med."},{"key":"214_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jneuroim.2006.06.017","volume":"179","author":"CA Kirvan","year":"2006","unstructured":"Kirvan, C. A., Swedo, S. E., Snider, L. A. & Cunningham, M. W. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J. Neuroimmunol. 179, 173\u2013179 (2006).","journal-title":"J. Neuroimmunol."},{"key":"214_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ajhg.2017.10.003","volume":"101","author":"S Kury","year":"2017","unstructured":"Kury, S. et al. De novo mutations in protein kinase genes CAMK2A and CAMK2B cause intellectual disability. Am. J. Hum. Genet. 101, 768\u2013788 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"214_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1089\/cap.2014.0048","volume":"25","author":"CJ Cox","year":"2015","unstructured":"Cox, C. J. et al. Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 25, 76\u201385 (2015).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"214_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073516","volume":"8","author":"H Ben-Pazi","year":"2013","unstructured":"Ben-Pazi, H., Stoner, J. A. & Cunningham, M. W. Dopamine receptor autoantibodies correlate with symptoms in Sydenham\u2019s chorea. PLoS. ONE 8, e73516 (2013).","journal-title":"PLoS. ONE"},{"key":"214_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1469-8749.2008.03217.x","volume":"51","author":"CI Akman","year":"2009","unstructured":"Akman, C. I., Patterson, M. C., Rubinstein, A. & Herzog, R. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev. Med. Child Neurol. 51, 563\u2013567 (2009).","journal-title":"Dev. Med. Child Neurol."},{"key":"214_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.pedneo.2013.01.016","volume":"54","author":"IJ Chou","year":"2013","unstructured":"Chou, I. J. et al. Limbic encephalitis in Taiwanese children and adolescence: a single center study. Pediatr. Neonatol. 54, 246\u2013253 (2013).","journal-title":"Pediatr. Neonatol."},{"key":"214_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/adc.2010.183897","volume":"96","author":"E Haberlandt","year":"2011","unstructured":"Haberlandt, E. et al. Limbic encephalitis in children and adolescents. Arch. Dis. Child. 96, 186\u2013191 (2011).","journal-title":"Arch. Dis. Child."},{"key":"214_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.pediatrneurol.2012.06.013","volume":"47","author":"JJ Lin","year":"2012","unstructured":"Lin, J. J. et al. Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus. Pediatr. Neurol. 47, 252\u2013258 (2012).","journal-title":"Pediatr. Neurol."},{"key":"214_CR31","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.1542\/peds.109.3.e50","volume":"109","author":"JA Olson","year":"2002","unstructured":"Olson, J. A., Olson, D. M., Sandborg, C., Alexander, S. & Buckingham, B. Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics 109, E50 (2002).","journal-title":"Pediatrics"},{"key":"214_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.pediatrneurol.2012.12.031","volume":"48","author":"S Saltik","year":"2013","unstructured":"Saltik, S., Turkes, M., Tuzun, E., Cakir, A. & Ulusoy, C. Peripheral neuropathy associated with antiglutamic acid decarboxylase antibodies. Pediatr. Neurol. 48, 403\u2013406 (2013).","journal-title":"Pediatr. Neurol."},{"key":"214_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.braindev.2012.08.003","volume":"35","author":"M Sanefuji","year":"2013","unstructured":"Sanefuji, M. et al. A case of childhood stiff-person syndrome with striatal lesions: a possible entity distinct from the classical adult form. Brain Dev. 35, 575\u2013578 (2013).","journal-title":"Brain Dev."},{"key":"214_CR34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/jnnp-2012-303807","volume":"84","author":"Y Hacohen","year":"2013","unstructured":"Hacohen, Y. et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J. Neurol. Neurosurg. Psychiatry 84, 748\u2013755 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"214_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12, 157\u2013165 (2013).","journal-title":"Lancet Neurol."},{"key":"214_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/0883073813501875","volume":"29","author":"O Scott","year":"2014","unstructured":"Scott, O. et al. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: an unusual cause of autistic regression in a toddler. J. Child Neurol. 29, 691\u2013694 (2014).","journal-title":"J. Child Neurol."},{"key":"214_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(11)60548-5","volume":"378","author":"C Creten","year":"2011","unstructured":"Creten, C. et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet (Lond., Engl.). 378, 98 (2011).","journal-title":"Lancet (Lond., Engl.)."},{"key":"214_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/dmcn.13169","volume":"58","author":"Y Hacohen","year":"2016","unstructured":"Hacohen, Y. et al. N-methyl-d-aspartate (NMDA) receptor antibodies encephalitis mimicking an autistic regression. Dev. Med. Child Neurol. 58, 1092\u20131094 (2016).","journal-title":"Dev. Med. Child Neurol."},{"key":"214_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/WNN.0b013e31828b6531","volume":"26","author":"S Najjar","year":"2013","unstructured":"Najjar, S. et al. Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review. Cogn. Behav. Neurol. 26, 36\u201349 (2013).","journal-title":"Cogn. Behav. Neurol."},{"key":"214_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00787-012-0245-1","volume":"21","author":"UK Rout","year":"2012","unstructured":"Rout, U. K., Mungan, N. K. & Dhossche, D. M. Presence of GAD65 autoantibodies in the serum of children with autism or ADHD. Eur. Child Adolesc. Psychiatry 21, 141\u2013147 (2012).","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"214_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13590840600681827","volume":"15","author":"M Boris","year":"2005","unstructured":"Boris, M., Goldblatt, A. & Edelson, S. M. Improvements in children with autism treated with intravenous gamma globulin. J. Nutr. Environ. Med. 15, 169\u2013176 (2005).","journal-title":"J. Nutr. Environ. Med."},{"key":"214_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/BF02172828","volume":"26","author":"S Gupta","year":"1996","unstructured":"Gupta, S., Aggarwal, S. & Heads, C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J. Autism Dev. Disord. 26, 439\u2013452 (1996).","journal-title":"J. Autism Dev. Disord."},{"key":"214_CR43","unstructured":"Oleske J. Another view of autism. UNMDNJ Research: 22\u201323, Winter 2004."},{"key":"214_CR44","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/sj.npp.1300130","volume":"28","author":"H Niederhofer","year":"2003","unstructured":"Niederhofer, H., Staffen, W. & Mair, A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology 28, 1014\u20131015 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"214_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1023\/A:1023096728131","volume":"29","author":"G DelGiudice-Asch","year":"1999","unstructured":"DelGiudice-Asch, G., Simon, L., Schmeidler, J., Cunningham-Rundles, C. & Hollander, E. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J. Autism Dev. Disord. 29, 157\u2013160 (1999).","journal-title":"J. Autism Dev. Disord."},{"key":"214_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/088307389801300207","volume":"13","author":"AV Plioplys","year":"1998","unstructured":"Plioplys, A. V. Intravenous immunoglobulin treatment of children with autism. J. Child Neurol. 13, 79\u201382 (1998).","journal-title":"J. Child Neurol."},{"key":"214_CR47","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"SJ Perlmutter","year":"1999","unstructured":"Perlmutter, S. J. et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet (Lond., Engl.). 354, 1153\u20131158 (1999).","journal-title":"Lancet (Lond., Engl.)."},{"key":"214_CR48","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1176\/ajp.155.11.1592","volume":"155","author":"SJ Perlmutter","year":"1998","unstructured":"Perlmutter, S. J. et al. A case of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Am. J. Psychiatry 155, 1592\u20131598 (1998).","journal-title":"Am. J. Psychiatry"},{"key":"214_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/cap.2014.0067","volume":"25","author":"M Kovacevic","year":"2015","unstructured":"Kovacevic, M., Grant, P. & Swedo, S. E. Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Child Adolesc. Psychopharmacol. 25, 65\u201369 (2015).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"214_CR50","doi-asserted-by":"crossref","unstructured":"Delhey L. M., et al. The effect of mitochondrial supplements on mitochondrial activity in children with autism spectrum disorder. J. Clin. Med. 6, E18 (2017).","DOI":"10.3390\/jcm6020018"},{"key":"214_CR51","first-page":"80","volume":"10","author":"RE Frye","year":"2016","unstructured":"Frye, R. E. et al. Blocking and binding folate receptor alpha autoantibodies identify novel autism spectrum disorder subgroups. Front. Neurosci. 10, 80 (2016).","journal-title":"Front. Neurosci."},{"key":"214_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/mp.2016.168","volume":"23","author":"RE Frye","year":"2016","unstructured":"Frye, R. E. et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol. Psychiatry 23, 247\u2013256 (2016).","journal-title":"Mol. Psychiatry"},{"key":"214_CR53","doi-asserted-by":"crossref","unstructured":"Frye R. E., et al. Thyroid dysfunction in children with autism spectrum disorder is associated with folate receptor alpha autoimmune disorder. J. Neuroendocrinol. 29 (2017).","DOI":"10.1111\/jne.12461"},{"key":"214_CR54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31887\/DCNS.2017.19.1\/mleboyer","volume":"19","author":"H Grea","year":"2017","unstructured":"Grea, H. et al. Clinical and autoimmune features of a patient with autism spectrum disorder seropositive for anti-NMDA-receptor autoantibody. Dialogues Clin. Neurosci. 19, 65\u201370 (2017).","journal-title":"Dialogues Clin. Neurosci."},{"key":"214_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/mp.2011.175","volume":"18","author":"RE Frye","year":"2013","unstructured":"Frye, R. E., Sequeira, J. M., Quadros, E. V., James, S. J. & Rossignol, D. A. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol. Psychiatry 18, 369\u2013381 (2013).","journal-title":"Mol. Psychiatry"},{"key":"214_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.14","volume":"3","author":"RE Frye","year":"2013","unstructured":"Frye, R. E. et al. Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study. Transl. Psychiatry 3, e237 (2013).","journal-title":"Transl. Psychiatry"},{"key":"214_CR57","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10803-013-1970-0","volume":"44","author":"AJ Kaat","year":"2014","unstructured":"Kaat, A. J., Lecavalier, L. & Aman, M. G. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J. Autism Dev. Disord. 44, 1103\u20131116 (2014).","journal-title":"J. Autism Dev. Disord."},{"key":"214_CR58","volume-title":"The Social Responsiveness Scale","author":"JN Constantino","year":"2002","unstructured":"Constantino, J. N. The Social Responsiveness Scale. (Western Psychological Services, Los Angeles, 2002)."},{"key":"214_CR59","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s10803-011-1178-0","volume":"41","author":"MJ Murray","year":"2011","unstructured":"Murray, M. J., Mayes, S. D. & Smith, L. A. Brief report: excellent agreement between two brief autism scales (Checklist for Autism Spectrum Disorder and Social Responsiveness Scale) completed independently by parents and the autism diagnostic interview-revised. J. Autism Dev. Disord. 41, 1586\u20131590 (2011).","journal-title":"J. Autism Dev. Disord."},{"key":"214_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bbacli.2015.08.001","volume":"4","author":"S Kalra","year":"2015","unstructured":"Kalra, S. et al. No evidence of antibodies against GAD65 and other specific antigens in children with autism. BBA Clin. 4, 81\u201384 (2015).","journal-title":"BBA Clin."},{"key":"214_CR61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbr.2016.09.003","volume":"316","author":"DK Chau","year":"2017","unstructured":"Chau, D. K., Choi, A. Y., Yang, W., Leung, W. N. & Chan, C. W. Downregulation of glutamatergic and GABAergic proteins in valproric acid associated social impairment during adolescence in mice. Behav. Brain Res. 316, 255\u2013260 (2017).","journal-title":"Behav. Brain Res."},{"key":"214_CR62","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbr.2016.08.006","volume":"314","author":"R Wei","year":"2016","unstructured":"Wei, R. et al. A single low dose of valproic acid in late prenatal life alters postnatal behavior and glutamic acid decarboxylase levels in the mouse. Behav. Brain Res. 314, 190\u2013198 (2016).","journal-title":"Behav. Brain Res."},{"key":"214_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neulet.2016.06.035","volume":"629","author":"L Olexova","year":"2016","unstructured":"Olexova, L., Stefanik, P. & Krskova, L. Increased anxiety-like behaviour and altered GABAergic system in the amygdala and cerebellum of VPA rats - An animal model of autism. Neurosci. Lett. 629, 9\u201314 (2016).","journal-title":"Neurosci. Lett."},{"key":"214_CR64","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/15592294.2015.1114202","volume":"10","author":"MA Labouesse","year":"2015","unstructured":"Labouesse, M. A., Dong, E., Grayson, D. R., Guidotti, A. & Meyer, U. Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex. Epigenetics 10, 1143\u20131155 (2015).","journal-title":"Epigenetics"},{"key":"214_CR65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbi.2013.07.006","volume":"33","author":"J Richetto","year":"2013","unstructured":"Richetto, J., Calabrese, F., Meyer, U. & Riva, M. A. Prenatal versus postnatal maternal factors in the development of infection-induced working memory impairments in mice. Brain Behav. Immun. 33, 190\u2013200 (2013).","journal-title":"Brain Behav. Immun."},{"key":"214_CR66","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/ar.21252","volume":"294","author":"GJ Blatt","year":"2011","unstructured":"Blatt, G. J. & Fatemi, S. H. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat. Rec. (Hoboken). 294, 1646\u20131652 (2011).","journal-title":"Anat. Rec. (Hoboken)."},{"key":"214_CR67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/aur.62","volume":"2","author":"J Yip","year":"2009","unstructured":"Yip, J., Soghomonian, J. J. & Blatt, G. J. Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. Autism Res. 2, 50\u201359 (2009).","journal-title":"Autism Res."},{"key":"214_CR68","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mus.25027","volume":"54","author":"NL Zalewski","year":"2016","unstructured":"Zalewski, N. L., Lennon, V. A., Lachance, D. H., Klein, C. J., Pittock, S. J. & McKeon, A. P\/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle Nerve 54, 220\u2013227 (2016).","journal-title":"Muscle Nerve"},{"key":"214_CR69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pediatrneurol.2016.06.004","volume":"62","author":"MC Spiciarich","year":"2016","unstructured":"Spiciarich, M. C. & Moshe, S. L. Voltage-gated P\/Q-type calcium channel antibodies associated with cerebellar degeneration. Pediatr. Neurol. 62, 43\u201346 (2016).","journal-title":"Pediatr. Neurol."},{"key":"214_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1874467208666150507105235","volume":"8","author":"AF Breitenkamp","year":"2015","unstructured":"Breitenkamp, A. F., Matthes, J. & Herzig, S. Voltage-gated calcium channels and autism spectrum disorders. Curr. Mol. Pharmacol. 8, 123\u2013132 (2015).","journal-title":"Curr. Mol. Pharmacol."},{"key":"214_CR71","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1007\/s10875-010-9402-9","volume":"30","author":"S Gupta","year":"2010","unstructured":"Gupta, S., Samra, D. & Agrawal, S. Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin. J. Clin. Immunol. 30, S90\u2013S96 (2010).","journal-title":"J. Clin. Immunol."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0214-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:24:41Z","timestamp":1671535481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0214-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0214-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"22 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kathleen Connery, Leanna Delhey, John autoantibody have no conflicts of interest to declare. Craig Shimasaki is the President & Chief Executive Officer and Madeleine W. Cunningham is the Chief Scientific Officer of Moleculera Labs, Inc., which provides the Cunningham Panel\u2122, an immune panel that is used in this study. Richard E Frye is on the Scientific Advisory Board of Iliad Neurosciences, Inc, which performs the folate receptor alpha autoantibody which was used in some patients in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"148"}}